Skip to main content

Mª Jesus Melia Grimal

Institutions of which they are part

Research technician
Neuromuscular and Mitochondrial Pathology
Vall Hebron Institut de Recerca

Mª Jesus Melia Grimal

Institutions of which they are part

Research technician
Neuromuscular and Mitochondrial Pathology
Vall Hebron Institut de Recerca

Projects

Models d'estudi de malalties degudes a manteniment defectuós del DNA mitocondrial

IP: Ramon Martí Seves
Collaborators: Mª Jesus Melia Grimal, Pau Mollá Zaragozá, Javier Francisco Ramón Pasías, Juan Luis Restrepo Vera
Funding agency: Instituto de Salud Carlos III
Funding: 208750
Reference: PI24/00838
Duration: 01/01/2025 - 31/12/2027

Estudi de malalties neuromusculars i mitocondrials

IP: Ramon Martí Seves
Collaborators: Estudi de malalties neuromusculars i mitocondrials, Elena García Arumí, Yolanda Cámara Navarro, Mª Jesus Melia Grimal, Tomàs Pinós Figueras, Javier Francisco Ramón Pasías, Estudi de malalties neuromusculars i mitocondrials, Estudi de malalties neuromusculars i mitocondrials
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 0.01
Reference: 2021 SGR 00894
Duration: 01/01/2022 - 30/06/2025

Eficacia preclínica del uso de desoxiribonucleósidos como tratamiento para los síndromes de depleción/deleciones multiples del DNA mitocondrial (MDDS). Ampliación a causas genéticas no exploradas.

IP: Ramon Martí Seves
Collaborators: Mª Jesus Melia Grimal, Javier Francisco Ramón Pasías
Funding agency: Instituto de Salud Carlos III
Funding: 153670
Reference: PI21/00554
Duration: 01/01/2022 - 31/12/2025

Validación funcional de variantes en el genoma mitocondrial y nuclear en pacientes con patologia mitocondrial

IP: Elena García Arumí
Collaborators: Mª Jesus Melia Grimal, Clara Carnicer Cáceres, Paula Fernández Álvarez
Funding agency: Instituto de Salud Carlos III
Funding: 102850
Reference: PI19/01772
Duration: 01/01/2020 - 31/12/2023

Related news

The projects, selected under the 2026 Health Research and CaixaImpulse Health Innovation calls, address topics ranging from new therapies for childhood neurological disorders and Parkinson’s disease to the treatment of mitochondrial diseases and cancer.

The clinical trial, which also involved Vall d’Hebron, shows that the new therapy improves survival by 86% in patients with thymidine kinase 2 deficiency (TK2d).

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.

Related professionals

Luz Elena Valderrama Orenday

Luz Elena Valderrama Orenday

Research technician
Childhood Cancer and Blood Disorders
Read more
Montserrat Romero Reinaldos

Montserrat Romero Reinaldos

Research technician
Clinical Neuroimmunology
Read more
Aina Bosch Badó

Aina Bosch Badó

Predoctoral researcher
Infection and immunity in pediatric patients
Read more
Sergio Lopez Gandul

Sergio Lopez Gandul

Research assistant
Molecular Imaging and Therapy
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.